Navepegritide
Navepegritide (TransCon CNP, Yuviwel)
Also known as: TransCon CNP, Yuviwel
A once-weekly prodrug of C-type natriuretic peptide, FDA-approved in February 2026 for achondroplasia in children aged two and older.
Overview
Navepegritide releases C-type natriuretic peptide slowly from a carrier, giving a weekly injection that counters the overactive FGFR3 signaling of achondroplasia. In the ApproaCH trial, annualized growth velocity was 5.89 cm per year versus 4.41 on placebo. The FDA granted accelerated approval on February 27, 2026, making it the second CNP-based drug after vosoritide.
Mechanism of action
Sustained-release CNP analog that stimulates natriuretic peptide receptor B, inhibiting the MAPK pathway downstream of FGFR3 in growth-plate cartilage.
Key studies & citations
- Human2026
FDA approves once-weekly Yuviwel (navepegritide) for children with achondroplasia
Accelerated approval February 27, 2026.
Ascendis Pharma press release - Human2025
Navepegritide in children with achondroplasia (ApproaCH)
Growth velocity 5.89 versus 4.41 cm per year.
JAMA Pediatrics
Frequently asked questions
Is navepegritide used for height in healthy children?
No. It is approved only for achondroplasia, a genetic skeletal dysplasia.